Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic

Chun Fan Chen, Yung Tai Chen, Tz Heng Chen, Fan Yu Chen, Yi Ping Yang, Mong Lien Wang, Teh Ia Huo, Yuh Lih Chang, Ann Charis Tan, Chih Ching Lin*

*此作品的通信作者

研究成果: Review article同行評審

1 引文 斯高帕斯(Scopus)

摘要

Sodium glucose cotransporter-2 inhibitors (SGLT2i), a novel antidiabetic drug blocks the reabsorption of glucose in proximal tubules of kidney, are demonstrated to have cardiovascular and renal benefits for people with diabetes. The benefits are associated with the significant increase of intrarenal angiotensin-converting enzyme II (ACE2) expression and blood volume contraction. However, the increased ACE2 may be detrimental to patients infected with the coronavirus infection 2019 (COVID-19), which is found to invade cells via the entry receptor of ACE2. Besides, an SGLT2i-induced natriuretic effect may also increase the risk of acute kidney injury and affect the hemodynamic stability during systemic infection disease. In this article, we explain the mechanisms why the use of SGLT2i in people with diabetes may lead to worse outcomes and suggest clinician to judiciously use it during COVID-19 pandemic.

原文English
頁(從 - 到)809-811
頁數3
期刊Journal of the Chinese Medical Association
83
發行號9
DOIs
出版狀態Published - 9月 2020

指紋

深入研究「Judicious use of sodium-glucose cotransporter 2 inhibitors in patients with diabetes on coronavirus-19 pandemic」主題。共同形成了獨特的指紋。

引用此